Sexually transmitted diseases and infections

Mel-Mont Medical announces the validation of its patented self-sampling technology, Mía by XytoTest®, for molecular screening using HPV-DNA and 7-Type mRNA E6/E7.

Wednesday, August 4, 2021 - 6:51pm

KLOKKARSTUA, Norway, Aug. 4, 2021 /PRNewswire/ -- Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women's health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest®, receives clinical validation as being equally effective to clinician-collected sampling.

Key Points: 
  • "Current estimates indicate that every year 569,847 women are diagnosed with cervical cancer, and 311,365 die from the disease.
  • Cervical cancer ranks as the third most frequent cancer among women in the world," according to Globocan information center on HPV and cancer.
  • The uniqueness of Ma by XytoTest empowers sexually active women to further their self-care opportunities and pre-screen for HPV-caused cancers.
  • PreTect AS, a fully ISO 13485:2016, CE/IVD certified, and FDA registered mRNA manufacturing facility based in Klokkarstua, Norway, is a wholly-owned subsidiary of Mel-Mont Medical, Inc.

AHF Commends the Resumption of HIV Treatment in Kenya – But More Is Needed

Monday, July 26, 2021 - 8:42pm

As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.

Key Points: 
  • As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.
  • The damage done to peoples lives and wellbeingparticularly childrens livesis irreversible and must never be repeated.
  • Ensure that HIV management is implemented holistically by taking into consideration prevention and diagnosis, care and treatment, and related essential commodities, including medications.
  • This is urgently needed to address current shortages of paediatric HIV treatment, viral load testing reagents, and HIV test kits.

New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium

Monday, July 26, 2021 - 1:02pm

For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.

Key Points: 
  • For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.
  • The 2015 CDC guidelines included M. genitalium as an emerging issue, but no FDA-cleared NAATs were available at that time11.
  • Hologic was first to market in 2019 with a NAAT for M. genitalium, and Hologics Aptima Mycoplasma genitalium Assay is specifically noted in the current guidelines1.
  • No FDA-cleared M. genitalium tests are available in the U.S. that detect antibiotic resistance, although Hologic is working to develop one.

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1

Monday, July 26, 2021 - 12:05pm

This trial builds on the encouraging results from the Companys previously completed IMC-1 phase 2a FM clinical study.

Key Points: 
  • This trial builds on the encouraging results from the Companys previously completed IMC-1 phase 2a FM clinical study.
  • This dual mechanism antiviral therapy is designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication.
  • The Company anticipates reporting top line results from the currently enrolling FORTRESS Phase 2b FM trial in mid-2022.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

Monday, July 26, 2021 - 12:00pm

Kaposi Sarcoma (KS) is an angioproliferative tumor associated with infection by Kaposi sarcoma-associated herpes virus (KSHV).

Key Points: 
  • Kaposi Sarcoma (KS) is an angioproliferative tumor associated with infection by Kaposi sarcoma-associated herpes virus (KSHV).
  • The identification of a viral etiology of KS helped explain the long-observed association between KS and immunosuppression, specifically CD4+ T cell lymphopenia, commonly seen with HIV infection.
  • In chronic uncontrolled HIV infection, physiologic doses of IL-7 are unable to prevent CD4+ lymphopenia.
  • Furthermore, lymphopenia-inducing insults that may occur in the treatment of KS with anti-neoplastic or radiation treatment could result in a prolonged CD4+ T cell depletion.

Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund

Thursday, July 22, 2021 - 5:49pm

Chembios delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembios supply chain, staffing, and liquidity, and other matters outside Chembios control.

Key Points: 
  • Chembios delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembios supply chain, staffing, and liquidity, and other matters outside Chembios control.
  • Chembio was first awarded the front-line testing algorithm position in Ethiopia in 2018 to screen for HIV.
  • Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted, respiratory and insect vector diseases.
  • Forward-looking statements include statements regarding the intent, belief or current expectations with respect to manufacturing, distribution, and sale of the HIV 1/2 STAT-PAK Assay pursuant to the purchase order from PFSCM.

LexaGene’s MiQLab Detects Common Bioreactor Contaminant up to 300 Times Faster than Conventional Methods

Tuesday, July 20, 2021 - 12:45pm

Last month, LexaGene announced it could detect Cutibacterium acnes 36 to 168 times faster than conventional methods.

Key Points: 
  • Last month, LexaGene announced it could detect Cutibacterium acnes 36 to 168 times faster than conventional methods.
  • We expect the time benefit of MiQLab Mycoplasma Test to be up to 300 times faster than conventional methods.
  • LexaGenes results demonstrate that the MiQLab system can serve as a valid alternative to lengthy traditional methods for mycoplasma detection.
  • Given the MiQLab can be up to 300 times faster than traditional culture testing (~2 hours versus ~28 days) for a definitive result, the MiQLab can provide a significant time advantage for biopharmaceutical manufacturers.

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis

Thursday, July 1, 2021 - 1:00pm

[1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.

Key Points: 
  • [1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.
  • The supplemental approval makes SOLOSEC the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV.
  • Research demonstrates that approximately 70% of women with trichomoniasis are PCR positive for BV,[2]" said Jon Stelzmiller, President Specialty, Lupin Pharmaceuticals, Inc.
  • SOLOSEC(secnidazole) 2 g oral granules is an antimicrobial agent indicatedfor the treatment of BV in adult women and trichomoniasis in adults.

AHF Launches New Campaigns “Hook Up With Us” Addressing 6th Straight Year of Increases in STDs and “AHF Is Resilience”

Saturday, June 19, 2021 - 11:00am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210619005059/en/
    In 2019, more than 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported, and were the most common STDs found.
  • Undoubtedly, this causes grave concern as STDs have the potential to lead to serious health consequences, especially if untreated.
  • Past AHF billboard campaigns addressing STDs include Gonorrhea Alert , launched in June of 2018 which was a nationwide effort to educate the public about a drug-resistant strain of the STD.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

Science Translational Medicine Publication: Innovative Molecules´ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections

Wednesday, June 16, 2021 - 7:00pm

The study entitled A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections was conducted by a team of researchers from the U.S. and Germany and was published today in Science Translational Medicine .

Key Points: 
  • The study entitled A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections was conducted by a team of researchers from the U.S. and Germany and was published today in Science Translational Medicine .
  • IM-250 is devoid of off-target activity observed with other anti-HSV drugs and of potential metabolites of previous drug candidates targeting helicase-primase.
  • At least 50 % of the population is infected with Herpes simplex virus type 1 (HSV-1), mostly herpes labialis, whereas approx.
  • 25% of the population is infected withHerpes simplex virus type 2 (HSV-2), mostly genital herpes, a sexually transmitted infection/disease.